MSLN and neoplasm: No evidence of on-target, off-tumor or therapy related toxicity was seen, and CAR T-cell persistence was associated with decreased levels of serum soluble MSLN-related peptide (SMRP) levels (>50% compared to pretreatment) and evidence of tumor response.